{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:27:20Z","timestamp":1793514440533,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s12325-018-0766-1","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T13:37:34Z","timestamp":1533908254000},"page":"1285-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Prostate Cancer in Primary Care"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-9087","authenticated-orcid":false,"given":"Samuel W. D.","family":"Merriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth","family":"Funston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"key":"766_CR1","unstructured":"Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon. 2013. http:\/\/globocan.iarc.fr. Accessed 24 May 2018."},{"issue":"18","key":"766_CR2","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive services task force recommendation statement. JAMA. 2018;319(18):1901\u201313.","journal-title":"JAMA"},{"key":"766_CR3","unstructured":"NICE. Suspected cancer: recognition and referral. 2015. p. 1\u201395. https:\/\/www.nice.org.uk\/guidance\/ng12."},{"key":"766_CR4","doi-asserted-by":"crossref","unstructured":"\u00d8ster\u00f8 \u00ed J\u00e1kupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ. 2018;361(1202):1\u20136. Available from https:\/\/www.bmj.com\/content\/bmj\/361\/bmj.k1202.full.pdf.","DOI":"10.1136\/bmj.k1202"},{"key":"766_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12875-018-0765-y","volume":"19","author":"D Jones","year":"2018","unstructured":"Jones D, Friend C, Dreher A, Allgar V, Macleod U. The diagnostic test accuracy of rectal examination for prostate cancer diagnosis in symptomatic patients: a systematic review. BMC Fam Pract. 2018;19:79.","journal-title":"BMC Fam Pract"},{"issue":"3","key":"766_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","volume":"68","author":"DJ Parekh","year":"2015","unstructured":"Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68(3):464\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.021.","journal-title":"Eur Urol"},{"key":"766_CR7","unstructured":"Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928\u201336. Available from http:\/\/www.nature.com\/articles\/s41588-018-0142-8."},{"key":"766_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"380","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, Bosaily AE-S, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;380:1\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1.","journal-title":"Lancet"},{"issue":"5","key":"766_CR9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MCS Wong","year":"2016","unstructured":"Wong MCS, Goggins WB, Wang HHX, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862\u201374. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.043.","journal-title":"Eur Urol"},{"key":"766_CR10","unstructured":"ONS. Cancer registration statistics, England: 2014. 2016;1\u201317. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/cancerregistrationstatisticsengland\/201."},{"issue":"10","key":"766_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0027130","volume":"6","author":"M Kici\u0144ski","year":"2011","unstructured":"Kici\u0144ski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One. 2011;6(10):1\u20137.","journal-title":"PLoS One"},{"issue":"16","key":"766_CR12","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/pros.21394","volume":"71","author":"L Fachal","year":"2011","unstructured":"Fachal L, G\u00f5mez-Caama\u00f1o A, Celeiro-Mu\u00f1oz C, et al. BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data. Prostate. 2011;71(16):1768\u201379.","journal-title":"Prostate"},{"issue":"10","key":"766_CR13","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/bjc.2012.146","volume":"106","author":"D Leongamornlert","year":"2012","unstructured":"Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697\u2013701.","journal-title":"Br J Cancer"},{"issue":"3","key":"766_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","volume":"23","author":"S Ryan","year":"2014","unstructured":"Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(3):437\u201349.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"766_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-015-0405-5","volume":"13","author":"T Lloyd","year":"2015","unstructured":"Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008\u20132010. BMC Med. 2015;13(1):1\u201310. https:\/\/doi.org\/10.1186\/s12916-015-0405-5.","journal-title":"BMC Med"},{"issue":"2","key":"766_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ijc.23500","volume":"123","author":"S Evans","year":"2008","unstructured":"Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black\u2013White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;123(2):430\u20135.","journal-title":"Int J Cancer"},{"issue":"1","key":"766_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.eururo.2007.02.047","volume":"53","author":"Y Ben-Shlomo","year":"2008","unstructured":"Ben-Shlomo Y, Evans S, Ibrahim F, et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS Cohort Study. Eur Urol. 2008;53(1):99\u2013105.","journal-title":"Eur Urol"},{"key":"766_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0022-5347(17)35487-3","volume":"150","author":"W Sakr","year":"1993","unstructured":"Sakr W, Haas G, Cassin B, Pontes J, Crissman J. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150:379\u201385.","journal-title":"J Urol"},{"issue":"6","key":"766_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","volume":"44","author":"R Rosen","year":"2003","unstructured":"Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637\u201349.","journal-title":"Eur Urol"},{"issue":"8","key":"766_CR20","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/ijc.23713","volume":"123","author":"RM Martin","year":"2008","unstructured":"Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TIL. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 cohort, Norway. Int J Cancer. 2008;123(8):1924\u20138.","journal-title":"Int J Cancer"},{"issue":"6","key":"766_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.eururo.2012.12.060","volume":"63","author":"DJ Whellan","year":"2013","unstructured":"Whellan DJ, Ellis SJ, Kraus WE, et al. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol. 2013;63(6):1021\u20137.","journal-title":"Eur Urol"},{"issue":"1\u20132","key":"766_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5489\/cuaj.4031","volume":"11","author":"A Bhindi","year":"2017","unstructured":"Bhindi A, Bhindi B, Kulkarni GS, et al. Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: analysis of a propensity score-matched cohort. J Can Urol Assoc. 2017;11(1\u20132):41\u20136.","journal-title":"J Can Urol Assoc"},{"issue":"486","key":"766_CR23","first-page":"31","volume":"53","author":"R Bruyninckx","year":"2003","unstructured":"Bruyninckx R, Buntinx F, Aertgeerts B, Van Casteren V. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice. Br J Gen Pract. 2003;53(486):31\u20135.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"766_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/2051415814548913","volume":"8","author":"JH Gan","year":"2015","unstructured":"Gan JH, Harris AC, Green JSA. Quantifying the risk of malignancy in patients with visible haematuria presenting to the emergency department. J Clin Urol. 2015;8(2):132\u20138.","journal-title":"J Clin Urol"},{"key":"766_CR25","doi-asserted-by":"crossref","unstructured":"Lin W-Y, Chang Y-H, Lin C-L, Kao C-H, Wu H-C. Erectile dysfunction and the risk of prostate cancer. Oncotarget. 2017;8(32):52690\u20138. Available from http:\/\/www.oncotarget.com\/fulltext\/17082.","DOI":"10.18632\/oncotarget.17082"},{"key":"766_CR26","unstructured":"Hamilton W, Sharp DJ, Peters TJ, Round AP. Clinical features of prostate cancer before diagnosis: a population-based, case-control study. Br J Gen Pract. 2006;56(531):756\u201362. Available from http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1920715&tool=pmcentrez&rendertype=abstract."},{"key":"766_CR27","unstructured":"Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract. 2004;54(505):617\u201321. Available from http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1324845&tool=pmcentrez&rendertype=abstract."},{"key":"766_CR28","unstructured":"Carter B, Albertsen P, Barry M, et al. Early detection of prostate cancer: AUA guideline. Linthicum: American Urological Association Education and Research; 2018. p. 1\u201328."},{"key":"766_CR29","unstructured":"Mottet N, Bellmunt J, Briers E, et al. EAU\u2013ESTRO\u2013ESUR\u2013SIOG guidelines on prostate cancer. European Association of Urology. 2017. Available from https:\/\/uroweb.org\/wp-content\/uploads\/09-Prostate-Cancer_2017_web.pdf."},{"key":"766_CR30","doi-asserted-by":"publisher","unstructured":"de Koning HJ, Gulati R, Moss SM, et al. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer. 2017. https:\/\/doi.org\/10.1002\/cncr.31178.","DOI":"10.1002\/cncr.31178"},{"key":"766_CR31","doi-asserted-by":"publisher","unstructured":"Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Ilic D, editor. Cochrane Database Syst Rev. 2013 Sep 1;(1):CD004720. https:\/\/doi.org\/10.1002\/14651858.cd004720.pub3%5cn","DOI":"10.1002\/14651858.cd004720.pub3%5cn"},{"issue":"4","key":"766_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ijc.31102","volume":"142","author":"EAM Heijnsdijk","year":"2018","unstructured":"Heijnsdijk EAM, Bangma CH, Borr\u00e0s JM, et al. Summary statement on screening for prostate cancer in Europe. Int J Cancer. 2018;142(4):741\u20136.","journal-title":"Int J Cancer"},{"issue":"9","key":"766_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319(9):883\u201395.","journal-title":"JAMA"},{"issue":"4","key":"766_CR34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.30474","volume":"123","author":"PF Pinsky","year":"2017","unstructured":"Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592\u20139.","journal-title":"Cancer"},{"key":"766_CR35","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13\u00a0years of follow-up. Lancet. 2014;384(9959):2027\u201335. Available from http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673614605250."},{"key":"766_CR36","doi-asserted-by":"publisher","first-page":"j1493","DOI":"10.1136\/bmj.j1493","volume":"357","author":"M Vedanayagam","year":"2017","unstructured":"Vedanayagam M, Kumar A, Madaan S. Lower urinary tract symptoms in an older man. BMJ. 2017;357:j1493.","journal-title":"BMJ"},{"issue":"1","key":"766_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1570-9124(03)00003-5","volume":"1","author":"HP Schmid","year":"2003","unstructured":"Schmid HP, Prikler L, Sturgeon CM, Semjonow A. Diagnosis of prostate cancer: the clinical use of prostate specific antigen. EAU Update Ser. 2003;1(1):3\u20138.","journal-title":"EAU Update Ser"},{"issue":"10","key":"766_CR38","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/pon.3815","volume":"24","author":"D Ilic","year":"2015","unstructured":"Ilic D, Jammal W, Chiarelli P, et al. Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review. Psychooncology. 2015;24(10):1303\u201315.","journal-title":"Psychooncology"},{"issue":"6","key":"766_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2013.05.049.","journal-title":"Eur Urol"},{"issue":"8","key":"766_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/jnci\/djj131","volume":"98","author":"IM Thompson","year":"2006","unstructured":"Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98(8):529\u201334. https:\/\/doi.org\/10.1093\/jnci\/djj131.","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"766_CR41","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1002\/pros.20840","volume":"68","author":"R Kranse","year":"2008","unstructured":"Kranse R, Roobol M, Schr\u00f6der FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate. 2008;68(15):1674\u201380.","journal-title":"Prostate"},{"issue":"5","key":"766_CR42","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/annonc\/mdu525","volume":"26","author":"KS Louie","year":"2015","unstructured":"Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26(5):848\u201364. https:\/\/doi.org\/10.1093\/annonc\/mdu525.","journal-title":"Ann Oncol"},{"issue":"3","key":"766_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.13314","volume":"117","author":"C Poyet","year":"2016","unstructured":"Poyet C, Nieboer D, Bhindi B, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary Europe. BJU Int. 2016;117(3):401\u20138. https:\/\/doi.org\/10.1111\/bju.13314.","journal-title":"BJU Int"},{"issue":"2","key":"766_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, Straubinger J, Selig K, et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol. 2018;74(2):197\u2013203. https:\/\/doi.org\/10.1016\/j.eururo.2018.05.003.","journal-title":"Eur Urol"},{"key":"766_CR45","unstructured":"NICE. Prostate cancer: diagnosis and management. London: National Institute for Health and Clinical Excellence; 2014. https:\/\/www.nice.org.uk\/guidance\/cg175\/resources\/prostate-cancer-diagnosis-and-management-pdf-35109753913285. Accessed 20 June 2018."},{"key":"766_CR46","doi-asserted-by":"crossref","unstructured":"Boesen L, Norgaard N, Logager V, et al. Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men: the biparametric MRI for detection of prostate cancer (BIDOC) study. JAMA Netw Open. 2018;1(2).","DOI":"10.1001\/jamanetworkopen.2018.0219"},{"key":"766_CR47","doi-asserted-by":"publisher","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1801993.","DOI":"10.1056\/NEJMoa1801993"},{"key":"766_CR48","doi-asserted-by":"crossref","unstructured":"Meng X, Rosenkrantz AB, Taneja SS. Role of prostate magnetic resonance imaging in active surveillance. Transl Androl Urol. 2017;6(3):444\u201352. Available from http:\/\/tau.amegroups.com\/article\/view\/15159\/15452.","DOI":"10.21037\/tau.2017.05.05"},{"issue":"16","key":"766_CR49","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gronberg","year":"2015","unstructured":"Gronberg H, Adolfsson J, Aly M, et al. Prostate cancer screening in men aged 50\u201369\u00a0years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16(16):1667\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(15)00361-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"766_CR50","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.eururo.2018.02.016","volume":"73","author":"DD Sjoberg","year":"2018","unstructured":"Sjoberg DD, Vickers AJ, Assel M, et al. Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men. Eur Urol. 2018;73(6):941\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.016.","journal-title":"Eur Urol"},{"issue":"3","key":"766_CR51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.eururo.2016.11.017","volume":"72","author":"DW Lin","year":"2017","unstructured":"Lin DW, Newcomb LF, Brown MD, et al. Evaluating the four kallikrein panel of the 4K score for prediction of high-grade prostate cancer in men in the canary prostate active surveillance study. Eur Urol. 2017;72(3):448\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.017.","journal-title":"Eur Urol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0766-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:31:16Z","timestamp":1724412676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0766-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0766-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"assertion":[{"value":"3 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}